All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-08-19T14:42:07.000Z

Expression of miR-155 in Acute Myeloid Leukemia and its clinical significance

Aug 19, 2016
Share:

Bookmark this article

Aberrant expression of microRNA-155 (miR-155) has been identified in Acute Myeloid Leukemia (AML) and may be related to clinical outcome, however, this still needs to be further characterized. Hu X. L. and Tang A. P. investigated the expression of miR-155 in bone marrow mononuclear cells (BMMNC) of 80 patients with AML and its clinical significance. Their findings were published in the Chinese Association of Pathophysiology’s Journal of Experimental Hematology.

Key Results

  • MiR-155 expression levels in the moderate prognostic group and poor prognostic group were significantly higher as compared with the favorable prognosis group (P<0.05, P<0.05)
  • The expression level of miR-155 did not significantly correlate with the clinical features of patients

In conclusion, although there is only a small pool of patients, overexpression of miR-155 correlated to poor prognosis in AML. However, no relationship between the levels of miR-155 and clinical features of AML was observed.

 

  1. Hu X. L. & Tang A. P. Expression of miR-155 in Acute Myeloid Leukemia and Its Clinical Significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Aug; 24(4): 980-984. DOI: 10.7534/j.issn.1009-2137.2016.04.004.
More about...

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox